Cipla announces investment led by Fidelity Growth Partners India for consumer healthcare business

The business will focus on opportunities arising from the shift from illness to wellness and self-care Cipla’s board has approved an investment by Fidelity Growth Partners India and US-based Fidelity Biosciences, through FI

Cipla appoints Samina Vaziralli onto the Board of Directors

Cipla has appointed Samina Vaziralli as Executive Director on its board. Vaziralli is the daughter of MK Hamied, Vice Chairman of the Board of Cipla.

Initiate ‘sell’ on Cipla as risks outweigh likely rewards

Cipla’s decade-long effort on inhaler development may finally bear fruit over the next five years.

Cipla, BMS settle Hepatitis B drug dispute out of court

The patent dispute between US-based pharma major Bristol-Myers Squibb (BMS) and Cipla over Entecavir...

Stempeutics receives Japan process patent for its stem cell drug ‘Stempeucel’

Stempeucel is derived from allogeneic pooled mesenchymal stromal cells extracted from the bone marrow of healthy, adult voluntary donors, is used for the treatment of CLI

Cipla gets US FDA approval for Lopinavir and ritonavir oral pellets

These are used for the treatment of AIDS in infants and young children

Maintain buy on Cipla with revised price target of Rs 750: Edelweiss

Cipla’sQ4FY15 Ebitda margin (16.4%) was below estimate with consolidation of acquired entities and bunching up of R&D diluting...

Cipla, Serum Institute agreement

Signs exclusive distribution agreement for flu vaccine ‘Nasovac-S’ for India Cipla has signed an agreement with Serum Institute of India (SII) to exclusively market flu vaccine Nasovac-S in India. Under this agreement, SI

Markets in for a roller-coaster ride, say experts

Expiry of May futures and options contracts on Thursday may add to volatility, they added.

financial market india

BMS, Cipla may settle patent row amicably

Bristol-Myers Squibb and Cipla are heading towards an amicable settlement on a long-stretched patent row over Entecavir, a pharmaceutical combination for treating Hepatitis B.

Cipla to acquire Brazil’s Duomed Produtos for Rs 2.6 crore

Cipla today said its UK subsidiary Cipla (EU) will acquire Brazilian firm Duomed Produtos Farmaceuticos for about Rs 2.6 crore

Cipla stake

Cipla launches generic drug Sofosbuvir in India

The drug will be sold under the brand name ‘Hepcvir'

Cipla’s gain in German firm’s drug patent loss

Spiriva patent revoked, Paves way for Cipla’s generic version

Cipla wins US$ 188.95 million of Global Fund ARV tender

The anti-retrovirals drugs will be manufactured in Cipla’s state-of-the-art manufacturing facilities in India, which has been approved by various international regulatory agencies Cipla has been awarded US $188.95 million o

Delhi High court bars Cipla from selling copy of Novartis respiratory drug Onbrez

An Indian court has barred Indian generic drugmaker Cipla Ltd from making or selling a cheaper copy of Novartis...

cipla shares bse sensex

Roche loses patent for osteoporosis drug in India

In a setback to Swiss pharma major Hoffmann-La Roche (Roche), the Chennai patent office has revoked a patent of the company for...

Buy Cipla on better margin outlook: BofA ML

Reiterate ‘buy’ on Cipla and set price target of R770 per share, which is based on 23x FY17e EPS and R40 per share as NPV of gSeretide pMDI...

Novartis sues India’s Cipla over respiratory drug Onbrez

Novartis AG said it had sued India's Cipla Ltd for infringing patents covering its respiratory drug Onbrez.

Cipla’s arm Meditab sells stake in Jiangsu for $18.5 million

The closing of the transaction is subject to receipt of applicable regulatory approvals in China

Meda Pharmaceuticals and Cipla sue Apotex to enforce Dymista patents

Meda holds the NDA to manufacture and market Dymista in the US for the treatment of seasonal allergic rhinitis

Cipla in distribution agreement with SII for paediatric vaccines in Europe

The collaboration enables Cipla to enter into the vaccines segment

Cipla shares fall almost 3% post Q2 results

Cipla had posted a net profit of Rs 358.06 crore during the same period of previous fiscal.

Income Tax Calculator, Budget 2019, How to Calculate Income Tax


Stock Market

Most Read


Top News


Related Articles